Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study.

Competing Interests: Conflicts of interest Dr Kim Papp has served as an investigator, speaker, advisor/consultant for and/or received grants/honoraria from AbbVie, Akros, Amgen, Anacor, Arcutis, Astellas, AstraZeneca, Baxalta, Baxter, Boehringer Ingelheim, Bristol Myers Squibb, CanFite, Celgene, Coherus, Dermira, Dow Pharma, Eli Lilly, Galapagos NV, Galderma, Genentech, GlaxoSmithKline, Incyte, Janssen, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Merck (MSD), Merck-Serono, Mitsubishi Pharma, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis, Sanofi Genzyme, Takeda, UCB, and Valeant. Dr Vimal H. Prajapati has been an advisor, speaker, consultant and/or investigator for and/or received grants from AbbVie, Actelion, Amgen, AnaptysBio, Apogee Therapeutics, Aralez, Arcutis, Arena, Asana, Aspen, Bausch Health/Valeant, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Cipher, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte, Janssen, LEO Pharma, Medexus, Nimbus Lakshmi, Novartis, Pediapharm, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, Tribute, and UCB. Dr Catherine Maari has served as an investigator, advisory board member, speaker, consultant for, and/or received honoraria or grants from AbbVie, UCB, , Celgene, Eli Lilly, Galderma, Bristol Myers Squibb, Arcutis,LEO Pharma, Janssen, Novartis, Bausch Health, and Pfizer. Mark Legault is an employee of Bausch Health, Canada Inc. Maxime Barakat is an employee of Bausch Health, Canada Inc. Dr Ron Vender has served as an advisor/consultant and speaker, and received grants and honoraria, from AbbVie, Amgen, Bausch Health, Celgene, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB.